AMDHD1 Inhibitors
Chemical inhibitors of AMDHD1 can impact its function through various biochemical pathways. Methotrexate, by inhibiting dihydrofolate reductase, leads to a decrease in tetrahydrofolate, which is crucial for the biosynthesis of nucleotides and therefore necessary for the metabolic processes that involve AMDHD1. 5-Fluorouracil takes a similar approach but targets a different enzyme, thymidylate synthase, essential for synthesizing thymidine monophosphate, a precursor of thymidine triphosphate, which is required for DNA repair and replication where AMDHD1 plays a role. Sulindac's inhibition of cyclooxygenases can lead to decreased prostaglandin synthesis, which can alter metabolic pathways that include AMDHD1's function. Triclosan disrupts fatty acid synthesis by inhibiting enoyl-acyl carrier protein reductase, potentially affecting AMDHD1 through changes in membrane dynamics and signaling pathways. Allopurinol impacts AMDHD1 by inhibiting xanthine oxidase, thereby affecting the balance of purine nucleotides, which act as substrates for AMDHD1.
In the same context, Raloxifene alters the transcription of metabolic genes co-regulated with AMDHD1 by inhibiting the estrogen-related receptor gamma. Pyrazinamide, after being converted to pyrazinoic acid, can interfere with energy production in cells, affecting AMDHD1-involved processes. Hydroxyurea targets ribonucleotide reductase, decreasing deoxyribonucleotide levels crucial for AMDHD1's role in DNA synthesis and repair. Levofloxacin, while primarily acting on bacteria, can cause oxidative stress in human cells, which may indirectly affect AMDHD1's function. 6-Thioguanine becomes incorporated into DNA and RNA, disturbing nucleotide metabolism and, consequently, AMDHD1 activity. Oxonic acid, a uricase inhibitor, influences purine catabolism, thus affecting the function of AMDHD1. Lastly, Acyclovir, once activated, can inhibit DNA polymerase, disrupting processes in which AMDHD1 is implicated.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate is a dihydrofolate reductase inhibitor. By inhibiting this enzyme, it leads to a decrease in tetrahydrofolate and thus can inhibit the one-carbon pool by limiting the methyl donor in thymidine and purine synthesis, which are necessary for the biosynthesis of nucleotides that are essential for the activity of AMDHD1. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
5-Fluorouracil inhibits thymidylate synthase, leading to a depletion of thymidine monophosphate and subsequently affecting the synthesis of thymidine triphosphate, a nucleotide necessary for DNA repair and replication processes that AMDHD1 is involved in. | ||||||
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $31.00 $84.00 $147.00 | 3 | |
Sulindac can inhibit cyclooxygenase-1 and cyclooxygenase-2, leading to a decrease in prostaglandin synthesis. Prostaglandins can regulate various metabolic pathways, including those related to the function of AMDHD1, thus their decrease can lead to the inhibition of AMDHD1's function. | ||||||
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $138.00 $400.00 | ||
Triclosan inhibits enoyl-acyl carrier protein reductase, which is involved in the fatty acid synthesis pathway. As fatty acids are vital components of cell membranes and signaling pathways, inhibiting their synthesis can alter membrane dynamics and related signaling pathways that involve AMDHD1. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol inhibits xanthine oxidase, an enzyme involved in the catabolism of purines to uric acid. By inhibiting this enzyme, it affects the purine salvage pathway and the balance of purine nucleotides, which are substrates and regulators of AMDHD1's activity. | ||||||
Raloxifene | 84449-90-1 | sc-476458 | 1 g | $802.00 | 3 | |
Raloxifene, a selective estrogen receptor modulator, can inhibit the estrogen-related receptor gamma (ERRγ). The inhibition of ERRγ can alter the transcription of metabolic genes that are co-regulated with AMDHD1, potentially leading to the functional inhibition of AMDHD1. | ||||||
Pyrazinamide | 98-96-4 | sc-205824 sc-205824A sc-205824B sc-205824C sc-205824D sc-205824E | 10 g 25 g 100 g 250 g 1 kg 5 kg | $48.00 $66.00 $87.00 $148.00 $474.00 $2231.00 | ||
Pyrazinamide is converted into pyrazinoic acid which disrupts the membrane potential and interferes with the energy production in microbial cells. In mammalian cells, such disruption can affect metabolic processes including those in which AMDHD1 is involved. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea inhibits ribonucleotide reductase, leading to a decrease in deoxyribonucleotide levels which are crucial for DNA synthesis and repair. As AMDHD1 is involved in nucleotide metabolism, inhibition by hydroxyurea can result in functional impairment of AMDHD1. | ||||||
Levofloxacin | 100986-85-4 | sc-252953 sc-252953B sc-252953A | 10 mg 250 mg 1 g | $39.00 $45.00 $53.00 | 3 | |
Levofloxacin acts by inhibiting bacterial DNA gyrase and topoisomerase IV, leading to the cessation of DNA replication. In human cells, it can cause oxidative stress and interact with enzymes involved in DNA and RNA processing, which could indirectly inhibit the function of AMDHD1. | ||||||
6-Thioguanine | 154-42-7 | sc-205587 sc-205587A | 250 mg 500 mg | $41.00 $53.00 | 3 | |
6-Thioguanine gets incorporated into DNA and RNA, causing damage and affecting the synthesis and repair processes. This incorporation can impair the nucleotide metabolism and influence the activity of enzymes like AMDHD1 which are involved in these pathways. | ||||||